<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34962221</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control.</ArticleTitle>
        <Pagination>
          <StartPage>10</StartPage>
          <EndPage>17</EndPage>
          <MedlinePgn>10-17</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2021.2015482</ELocationID>
        <Abstract>
          <AbstractText>Aerosol therapy is used to deliver medical therapeutics directly to the airways to treat respiratory conditions. A potential consequence of this form of treatment is the release of fugitive aerosols, both patient derived and medical, into the environment and the subsequent exposure of caregivers and bystanders to potential viral infections. This study examined the release of these fugitive aerosols during a standard aerosol therapy to a simulated adult patient. An aerosol holding chamber and mouthpiece were connected to a representative head model and breathing simulator. A combination of laser and Schlieren imaging was used to non-invasively visualize the release and dispersion of fugitive aerosol particles. Time-varying aerosol particle number concentrations and size distributions were measured with optical particle sizers at clinically relevant positions to the simulated patient. The influence of breathing pattern, normal and distressed, supplemental air flow, at 0.2 and 6 LPM, and the addition of a bacterial filter to the exhalation port of the mouthpiece were assessed. Images showed large quantities of fugitive aerosols emitted from the unfiltered mouthpiece. The images and particle counter data show that the addition of a bacterial filter limited the release of these fugitive aerosols, with the peak fugitive aerosol concentrations decreasing by 47.3-83.3%, depending on distance from the simulated patient. The addition of a bacterial filter to the mouthpiece significantly reduces the levels of fugitive aerosols emitted during a simulated aerosol therapy, <i>p</i>≤ .05, and would greatly aid in reducing healthcare worker and bystander exposure to potentially harmful fugitive aerosols.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mac Giolla Eain</LastName>
            <ForeName>Marc</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Aerogen Ltd, IDA Business Park, Galway, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cahill</LastName>
            <ForeName>Ronan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, UCD Centre for Precision Surgery, University College Dublin, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>MacLoughlin</LastName>
            <ForeName>Ronan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Aerogen Ltd, IDA Business Park, Galway, Ireland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nolan</LastName>
            <ForeName>Kevin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>School of Mechanical and Materials Engineering, University College Dublin, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000336">Aerosols</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000336" MajorTopicYN="Y">Aerosols</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
          <QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="Y">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017053" MajorTopicYN="N">Infection Control</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017758" MajorTopicYN="N">Infectious Disease Transmission, Patient-to-Professional</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009330" MajorTopicYN="Y">Nebulizers and Vaporizers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012138" MajorTopicYN="Y">Respiratory Therapy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Schlieren imaging</Keyword>
        <Keyword MajorTopicYN="N">aerosol therapy</Keyword>
        <Keyword MajorTopicYN="N">aerosol visualization</Keyword>
        <Keyword MajorTopicYN="N">fugitive emissions</Keyword>
        <Keyword MajorTopicYN="N">vibrating mesh nebulizer</Keyword>
        <Keyword MajorTopicYN="N">viral infections</Keyword>
      </KeywordList>
      <CoiStatement>MMGE and RML are employees of Aerogen Limited. KN and RC have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>28</Day>
          <Hour>8</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34962221</ArticleId>
        <ArticleId IdType="pmc">PMC8725970</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2021.2015482</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Acosta MAT, Singer BD. (2020). Pathogenesis of COVID-19-induced ARDS: implications for an aging population. Eur Respir J
56:2002049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7397945</ArticleId>
            <ArticleId IdType="pubmed">32747391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agarwal A, Basmaji J, Muttalib F, et al.  (2020). High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. Can J Anaesth
67:1217–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7294988</ArticleId>
            <ArticleId IdType="pubmed">32542464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ari A, Fink JB, Pilbeam SP. (2016). Secondhand aerosol exposure during mechanical ventilation with and without expiratory filters: an in-vitro study. Indian J Respir Care
5:677–82.</Citation>
        </Reference>
        <Reference>
          <Citation>Badraoui R, Alrashedi MM, Bardakci F. (2020). Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19. J Biomol Struct Dyn
39:6842–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7484582</ArticleId>
            <ArticleId IdType="pubmed">32752936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett G, Joyce M, Fernández EF, MacLoughlin R. (2019). Comparison of aerosol delivery across combinations of drug delivery interfaces with and without concurrent high-flow nasal therapy. Intensive Care Med Exp
7:20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6447636</ArticleId>
            <ArticleId IdType="pubmed">30945044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett G, Joyce M, Sweeney L, MacLoughlin R. (2018). In vitro determination of the main effects in the design of high-flow nasal therapy systems with respect to aerosol performance. Pulm Ther
4:73–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6967237</ArticleId>
            <ArticleId IdType="pubmed">32026245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett G, Joyce M, Sweeney L, MacLoughlin R. (2019). In vitro study of the effect of breathing pattern on aerosol delivery during high-flow nasal therapy. Pulm Ther
5:43–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6967176</ArticleId>
            <ArticleId IdType="pubmed">32026423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhashyam AR, Wolf MT, Marcinkowski AL, et al.  (2008). Aerosol delivery through nasal cannulas: an in vitro study. J Aerosol Med Pulm Drug Deliv
21:181–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18518794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciuzas D, Prasauskas T, Krugly E, et al.  (2015). Characterization of indoor aerosol temporal variations for the real-time management of indoor air quality. Atmos Environ
118:107–17.</Citation>
        </Reference>
        <Reference>
          <Citation>Cortegiani A, Accurso G, Mercadante S, et al.  (2018). High flow nasal therapy in perioperative medicine: from operating room to general ward. BMC Anesthesiol
18:8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6230300</ArticleId>
            <ArticleId IdType="pubmed">30414608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dailey PA, Harwood R, Walsh K, et al.  (2017). Aerosol delivery through adult high flow nasal cannula with heliox and oxygen. Respir Care
62:1186–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28588117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernández Fernández E, Joyce M, O’Sullivan A, Macloughlin R. (2021). Evaluation of aerosol therapy during the escalation of care in a model of adult cystic fibrosis. Antibiotics
10:472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8142975</ArticleId>
            <ArticleId IdType="pubmed">33919035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hui DS, Chow BK, Chu LCY, et al.  (2009). Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest
135:648–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7094435</ArticleId>
            <ArticleId IdType="pubmed">19265085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hui DS, Chow BK, Lo T, et al.  (2015). Exhaled air dispersion during noninvasive ventilation via helmets and a total facemask. Chest
147:1336–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7094250</ArticleId>
            <ArticleId IdType="pubmed">25392954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hui DS, Hall SD, Chan MTV, et al.  (2007). Exhaled air dispersion during oxygen delivery via a simple oxygen mask. Chest
132:540–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7094533</ArticleId>
            <ArticleId IdType="pubmed">17573505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hunter JC, Nguyen D, Aden B, et al.  (2016). Transmission of Middle East Respiratory Syndrome coronavirus infections in healthcare settings, Abu Dhabi. Emerg Infect Dis
22:647–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4806977</ArticleId>
            <ArticleId IdType="pubmed">26981708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ISO . (2013). ISO 27427:2013 – anaesthetic and respiratory equipment — nebulizing systems and components, (Geneva, ISO; US Pharmacopoeia).</Citation>
        </Reference>
        <Reference>
          <Citation>Jackson T, Deibert D, Wyatt G, et al.  (2020). Classification of aerosol-generating procedures: a rapid systematic review. BMJ Open Respir Res
7:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7549490</ArticleId>
            <ArticleId IdType="pubmed">33040021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joyce M, McGrath JA, Mac Giolla Eain M, et al.  (2021). Nebuliser type influences both patient-derived bioaerosol emissions and ventilation parameters during mechanical ventilation. Pharmaceutics
13:199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7912998</ArticleId>
            <ArticleId IdType="pubmed">33540764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Guan X, Wu P, et al.  (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med
382:1199–207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7121484</ArticleId>
            <ArticleId IdType="pubmed">31995857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Ning Z, Chen Y, et al.  (2020). Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature
582:557–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32340022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loeb M, McGeer A, Henry B, et al.  (2004). SARS among critical care nurses, Toronto. Emerg Infect Dis
10:251–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3322898</ArticleId>
            <ArticleId IdType="pubmed">15030692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long CM, Suh HH, Catalano PJ, Koutrakis P. (2001). Using time- and size-resolved particulate data to quantify indoor penetration and deposition behavior. Environ Sci Technol
35:2089–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11393992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mac Giolla Eain M, Joyce M, O’Sullivan A, et al.  (2021). An in vitro investigation into the release of fugitive medical aerosols into the environment during manual ventilation. J Hosp Infect
108:135–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33296706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malik Peiris JS, Poon LLM, Guan Y. (2009). Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. J Clin Virol
45:169–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4894826</ArticleId>
            <ArticleId IdType="pubmed">19540800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGrath JA, O’Sullivan A, Bennett G, et al.  (2019a). Investigation of the quantity of exhaled aerosols released into the environment during nebulisation. Pharmaceutics
11:75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6409895</ArticleId>
            <ArticleId IdType="pubmed">30759879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGrath JA, O’Toole C, Bennett G, et al.  (2019b). Investigation of fugitive aerosols released into the environment during high-flow therapy. Pharmaceutics
11:254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6630289</ArticleId>
            <ArticleId IdType="pubmed">31159408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Neil CA, Li J, Leavey A, et al.  (2017). Characterization of aerosols generated during patient care activities. Clin Infect Dis
65:1342–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Ong SWX, Tan YK, Chia PY, et al.  (2020). Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA
323:1610–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7057172</ArticleId>
            <ArticleId IdType="pubmed">32129805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Réminiac F, Vecellio L, Heuzé-Vourc’h N, et al.  (2016). Aerosol therapy in adults receiving high flow nasal cannula oxygen therapy. J Aerosol Med Pulm Drug Deliv
29:134–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26196740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rygg A, Longest PW. (2016). Absorption and clearance of pharmaceutical aerosols in the human nose: development of a CFD model. J Aerosol Med Pulm Drug Deliv
29:416–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8662553</ArticleId>
            <ArticleId IdType="pubmed">26824178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saeed H, Harb HS, Madney YM, Abdelrahim MEA. (2021). Aerosol delivery via noninvasive ventilation: role of models and bioanalysis. Ann Transl Med
9:589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8105861</ArticleId>
            <ArticleId IdType="pubmed">33987287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Settles GS. (2001). Schlieren and shadowgraph techniques: visualizing phenomena in transparent media. Springer Science Business Media (Berlin, Germany).</Citation>
        </Reference>
        <Reference>
          <Citation>Sherman M. (1992). Simplified modeling for infiltration and radon entry. Thermal Performance of the Exterior Envelopes of Buildings Conference; Clearwater Beach, FL.</Citation>
        </Reference>
        <Reference>
          <Citation>Sim ES, Dharmarajan H, Sai D, et al.  (2021). Novel use of vitamin B2 as a fluorescent tracer in aerosol and droplet contamination models in otolaryngology. Ann Otol Rhinol Laryngol
130:280–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7429918</ArticleId>
            <ArticleId IdType="pubmed">32795090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simonds AK, Hanak A, Chatwin M, et al.  (2010). Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health Technol Assess
14:131–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20923611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takazono T, Yamamoto K, Okamoto R, et al.  (2021). Effects of surgical masks on droplet dispersion under various oxygen delivery modalities. Crit Care
25:4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7912960</ArticleId>
            <ArticleId IdType="pubmed">33639973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang JW, Liebner TJ, Craven BA, Settles GS. (2009). A Schlieren optical study of the human cough with and without wearing masks for aerosol infection control. J R Soc Interface
6:727–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2843945</ArticleId>
            <ArticleId IdType="pubmed">19815575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thielicke W, Stamhuis EJ. (2014). PIVlab – towards user-friendly, affordable and accurate digital particle image velocimetry in Matlab. J Open Res Softw 2.</Citation>
        </Reference>
        <Reference>
          <Citation>Tran K, Cimon K, Severn M, et al.  (2012). Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLOS One
7:e35797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3338532</ArticleId>
            <ArticleId IdType="pubmed">22563403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Doremalen N, Bushmaker T, Morris DH, et al.  (2020). Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med
382:1564–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7121658</ArticleId>
            <ArticleId IdType="pubmed">32182409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO . (1730). A multicentre collaboration to investigate the cause of severe acute respiratory syndrome. Lancet
361:3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7119328</ArticleId>
            <ArticleId IdType="pubmed">12767752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO . (2014). Infection prevention and control of epidemic- and pandemic-prone acute respiratory infections in health care. Available at: http://apps.who.int/iris/bitstream/handle/10665/112656/9789241507134_eng.pdf [last accessed 20 Aug 2021].</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24983124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wittgen BPH, Kunst PWA, Perkins WR, et al.  (2006). Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J Aerosol Med
19:385–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17034313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xi J, Kim J, Si XA. (2014). Effects of nostril orientation on airflow dynamics, heat exchange, and particle depositions in human noses. Eur J Mech B Fluids
6:567–77.</Citation>
        </Reference>
        <Reference>
          <Citation>Zumla A, Hui DS, Perlman S. (2015). Middle East Respiratory Syndrome. Lancet
386:995–1007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4721578</ArticleId>
            <ArticleId IdType="pubmed">26049252</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34962221</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control.</ArticleTitle>
        <Pagination>
          <StartPage>10</StartPage>
          <EndPage>17</EndPage>
          <MedlinePgn>10-17</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2021.2015482</ELocationID>
        <Abstract>
          <AbstractText>Aerosol therapy is used to deliver medical therapeutics directly to the airways to treat respiratory conditions. A potential consequence of this form of treatment is the release of fugitive aerosols, both patient derived and medical, into the environment and the subsequent exposure of caregivers and bystanders to potential viral infections. This study examined the release of these fugitive aerosols during a standard aerosol therapy to a simulated adult patient. An aerosol holding chamber and mouthpiece were connected to a representative head model and breathing simulator. A combination of laser and Schlieren imaging was used to non-invasively visualize the release and dispersion of fugitive aerosol particles. Time-varying aerosol particle number concentrations and size distributions were measured with optical particle sizers at clinically relevant positions to the simulated patient. The influence of breathing pattern, normal and distressed, supplemental air flow, at 0.2 and 6 LPM, and the addition of a bacterial filter to the exhalation port of the mouthpiece were assessed. Images showed large quantities of fugitive aerosols emitted from the unfiltered mouthpiece. The images and particle counter data show that the addition of a bacterial filter limited the release of these fugitive aerosols, with the peak fugitive aerosol concentrations decreasing by 47.3-83.3%, depending on distance from the simulated patient. The addition of a bacterial filter to the mouthpiece significantly reduces the levels of fugitive aerosols emitted during a simulated aerosol therapy, <i>p</i>≤ .05, and would greatly aid in reducing healthcare worker and bystander exposure to potentially harmful fugitive aerosols.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mac Giolla Eain</LastName>
            <ForeName>Marc</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Aerogen Ltd, IDA Business Park, Galway, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cahill</LastName>
            <ForeName>Ronan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, UCD Centre for Precision Surgery, University College Dublin, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>MacLoughlin</LastName>
            <ForeName>Ronan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Aerogen Ltd, IDA Business Park, Galway, Ireland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nolan</LastName>
            <ForeName>Kevin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>School of Mechanical and Materials Engineering, University College Dublin, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000336">Aerosols</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000336" MajorTopicYN="Y">Aerosols</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
          <QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="Y">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017053" MajorTopicYN="N">Infection Control</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017758" MajorTopicYN="N">Infectious Disease Transmission, Patient-to-Professional</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009330" MajorTopicYN="Y">Nebulizers and Vaporizers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012138" MajorTopicYN="Y">Respiratory Therapy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Schlieren imaging</Keyword>
        <Keyword MajorTopicYN="N">aerosol therapy</Keyword>
        <Keyword MajorTopicYN="N">aerosol visualization</Keyword>
        <Keyword MajorTopicYN="N">fugitive emissions</Keyword>
        <Keyword MajorTopicYN="N">vibrating mesh nebulizer</Keyword>
        <Keyword MajorTopicYN="N">viral infections</Keyword>
      </KeywordList>
      <CoiStatement>MMGE and RML are employees of Aerogen Limited. KN and RC have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>28</Day>
          <Hour>8</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34962221</ArticleId>
        <ArticleId IdType="pmc">PMC8725970</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2021.2015482</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Acosta MAT, Singer BD. (2020). Pathogenesis of COVID-19-induced ARDS: implications for an aging population. Eur Respir J
56:2002049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7397945</ArticleId>
            <ArticleId IdType="pubmed">32747391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agarwal A, Basmaji J, Muttalib F, et al.  (2020). High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. Can J Anaesth
67:1217–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7294988</ArticleId>
            <ArticleId IdType="pubmed">32542464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ari A, Fink JB, Pilbeam SP. (2016). Secondhand aerosol exposure during mechanical ventilation with and without expiratory filters: an in-vitro study. Indian J Respir Care
5:677–82.</Citation>
        </Reference>
        <Reference>
          <Citation>Badraoui R, Alrashedi MM, Bardakci F. (2020). Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19. J Biomol Struct Dyn
39:6842–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7484582</ArticleId>
            <ArticleId IdType="pubmed">32752936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett G, Joyce M, Fernández EF, MacLoughlin R. (2019). Comparison of aerosol delivery across combinations of drug delivery interfaces with and without concurrent high-flow nasal therapy. Intensive Care Med Exp
7:20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6447636</ArticleId>
            <ArticleId IdType="pubmed">30945044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett G, Joyce M, Sweeney L, MacLoughlin R. (2018). In vitro determination of the main effects in the design of high-flow nasal therapy systems with respect to aerosol performance. Pulm Ther
4:73–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6967237</ArticleId>
            <ArticleId IdType="pubmed">32026245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett G, Joyce M, Sweeney L, MacLoughlin R. (2019). In vitro study of the effect of breathing pattern on aerosol delivery during high-flow nasal therapy. Pulm Ther
5:43–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6967176</ArticleId>
            <ArticleId IdType="pubmed">32026423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhashyam AR, Wolf MT, Marcinkowski AL, et al.  (2008). Aerosol delivery through nasal cannulas: an in vitro study. J Aerosol Med Pulm Drug Deliv
21:181–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18518794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciuzas D, Prasauskas T, Krugly E, et al.  (2015). Characterization of indoor aerosol temporal variations for the real-time management of indoor air quality. Atmos Environ
118:107–17.</Citation>
        </Reference>
        <Reference>
          <Citation>Cortegiani A, Accurso G, Mercadante S, et al.  (2018). High flow nasal therapy in perioperative medicine: from operating room to general ward. BMC Anesthesiol
18:8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6230300</ArticleId>
            <ArticleId IdType="pubmed">30414608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dailey PA, Harwood R, Walsh K, et al.  (2017). Aerosol delivery through adult high flow nasal cannula with heliox and oxygen. Respir Care
62:1186–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28588117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernández Fernández E, Joyce M, O’Sullivan A, Macloughlin R. (2021). Evaluation of aerosol therapy during the escalation of care in a model of adult cystic fibrosis. Antibiotics
10:472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8142975</ArticleId>
            <ArticleId IdType="pubmed">33919035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hui DS, Chow BK, Chu LCY, et al.  (2009). Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest
135:648–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7094435</ArticleId>
            <ArticleId IdType="pubmed">19265085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hui DS, Chow BK, Lo T, et al.  (2015). Exhaled air dispersion during noninvasive ventilation via helmets and a total facemask. Chest
147:1336–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7094250</ArticleId>
            <ArticleId IdType="pubmed">25392954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hui DS, Hall SD, Chan MTV, et al.  (2007). Exhaled air dispersion during oxygen delivery via a simple oxygen mask. Chest
132:540–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7094533</ArticleId>
            <ArticleId IdType="pubmed">17573505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hunter JC, Nguyen D, Aden B, et al.  (2016). Transmission of Middle East Respiratory Syndrome coronavirus infections in healthcare settings, Abu Dhabi. Emerg Infect Dis
22:647–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4806977</ArticleId>
            <ArticleId IdType="pubmed">26981708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ISO . (2013). ISO 27427:2013 – anaesthetic and respiratory equipment — nebulizing systems and components, (Geneva, ISO; US Pharmacopoeia).</Citation>
        </Reference>
        <Reference>
          <Citation>Jackson T, Deibert D, Wyatt G, et al.  (2020). Classification of aerosol-generating procedures: a rapid systematic review. BMJ Open Respir Res
7:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7549490</ArticleId>
            <ArticleId IdType="pubmed">33040021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joyce M, McGrath JA, Mac Giolla Eain M, et al.  (2021). Nebuliser type influences both patient-derived bioaerosol emissions and ventilation parameters during mechanical ventilation. Pharmaceutics
13:199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7912998</ArticleId>
            <ArticleId IdType="pubmed">33540764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Guan X, Wu P, et al.  (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med
382:1199–207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7121484</ArticleId>
            <ArticleId IdType="pubmed">31995857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Ning Z, Chen Y, et al.  (2020). Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature
582:557–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32340022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loeb M, McGeer A, Henry B, et al.  (2004). SARS among critical care nurses, Toronto. Emerg Infect Dis
10:251–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3322898</ArticleId>
            <ArticleId IdType="pubmed">15030692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long CM, Suh HH, Catalano PJ, Koutrakis P. (2001). Using time- and size-resolved particulate data to quantify indoor penetration and deposition behavior. Environ Sci Technol
35:2089–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11393992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mac Giolla Eain M, Joyce M, O’Sullivan A, et al.  (2021). An in vitro investigation into the release of fugitive medical aerosols into the environment during manual ventilation. J Hosp Infect
108:135–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33296706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malik Peiris JS, Poon LLM, Guan Y. (2009). Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. J Clin Virol
45:169–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4894826</ArticleId>
            <ArticleId IdType="pubmed">19540800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGrath JA, O’Sullivan A, Bennett G, et al.  (2019a). Investigation of the quantity of exhaled aerosols released into the environment during nebulisation. Pharmaceutics
11:75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6409895</ArticleId>
            <ArticleId IdType="pubmed">30759879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGrath JA, O’Toole C, Bennett G, et al.  (2019b). Investigation of fugitive aerosols released into the environment during high-flow therapy. Pharmaceutics
11:254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6630289</ArticleId>
            <ArticleId IdType="pubmed">31159408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Neil CA, Li J, Leavey A, et al.  (2017). Characterization of aerosols generated during patient care activities. Clin Infect Dis
65:1342–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Ong SWX, Tan YK, Chia PY, et al.  (2020). Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA
323:1610–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7057172</ArticleId>
            <ArticleId IdType="pubmed">32129805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Réminiac F, Vecellio L, Heuzé-Vourc’h N, et al.  (2016). Aerosol therapy in adults receiving high flow nasal cannula oxygen therapy. J Aerosol Med Pulm Drug Deliv
29:134–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26196740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rygg A, Longest PW. (2016). Absorption and clearance of pharmaceutical aerosols in the human nose: development of a CFD model. J Aerosol Med Pulm Drug Deliv
29:416–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8662553</ArticleId>
            <ArticleId IdType="pubmed">26824178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saeed H, Harb HS, Madney YM, Abdelrahim MEA. (2021). Aerosol delivery via noninvasive ventilation: role of models and bioanalysis. Ann Transl Med
9:589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8105861</ArticleId>
            <ArticleId IdType="pubmed">33987287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Settles GS. (2001). Schlieren and shadowgraph techniques: visualizing phenomena in transparent media. Springer Science Business Media (Berlin, Germany).</Citation>
        </Reference>
        <Reference>
          <Citation>Sherman M. (1992). Simplified modeling for infiltration and radon entry. Thermal Performance of the Exterior Envelopes of Buildings Conference; Clearwater Beach, FL.</Citation>
        </Reference>
        <Reference>
          <Citation>Sim ES, Dharmarajan H, Sai D, et al.  (2021). Novel use of vitamin B2 as a fluorescent tracer in aerosol and droplet contamination models in otolaryngology. Ann Otol Rhinol Laryngol
130:280–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7429918</ArticleId>
            <ArticleId IdType="pubmed">32795090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simonds AK, Hanak A, Chatwin M, et al.  (2010). Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health Technol Assess
14:131–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20923611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takazono T, Yamamoto K, Okamoto R, et al.  (2021). Effects of surgical masks on droplet dispersion under various oxygen delivery modalities. Crit Care
25:4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7912960</ArticleId>
            <ArticleId IdType="pubmed">33639973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang JW, Liebner TJ, Craven BA, Settles GS. (2009). A Schlieren optical study of the human cough with and without wearing masks for aerosol infection control. J R Soc Interface
6:727–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2843945</ArticleId>
            <ArticleId IdType="pubmed">19815575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thielicke W, Stamhuis EJ. (2014). PIVlab – towards user-friendly, affordable and accurate digital particle image velocimetry in Matlab. J Open Res Softw 2.</Citation>
        </Reference>
        <Reference>
          <Citation>Tran K, Cimon K, Severn M, et al.  (2012). Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLOS One
7:e35797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3338532</ArticleId>
            <ArticleId IdType="pubmed">22563403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Doremalen N, Bushmaker T, Morris DH, et al.  (2020). Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med
382:1564–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7121658</ArticleId>
            <ArticleId IdType="pubmed">32182409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO . (1730). A multicentre collaboration to investigate the cause of severe acute respiratory syndrome. Lancet
361:3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7119328</ArticleId>
            <ArticleId IdType="pubmed">12767752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO . (2014). Infection prevention and control of epidemic- and pandemic-prone acute respiratory infections in health care. Available at: http://apps.who.int/iris/bitstream/handle/10665/112656/9789241507134_eng.pdf [last accessed 20 Aug 2021].</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24983124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wittgen BPH, Kunst PWA, Perkins WR, et al.  (2006). Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J Aerosol Med
19:385–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17034313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xi J, Kim J, Si XA. (2014). Effects of nostril orientation on airflow dynamics, heat exchange, and particle depositions in human noses. Eur J Mech B Fluids
6:567–77.</Citation>
        </Reference>
        <Reference>
          <Citation>Zumla A, Hui DS, Perlman S. (2015). Middle East Respiratory Syndrome. Lancet
386:995–1007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4721578</ArticleId>
            <ArticleId IdType="pubmed">26049252</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
